PanTheryx Invests in the Future Potential of Colostrum with Multiple Acquisitions

PanTheryx becomes the premier global supplier of colostrum; only company in the world with multiple manufacturing sites
As reported on Business Wire February 14, 2017

BOULDER, Colo.–(BUSINESS WIRE)–Aiming to maximize the potential of bovine colostrum to benefit global health, PanTheryx is announcing two major acquisitions that make it the world’s premiere manufacturer of nutrient rich colostrum. In separate purchases, PanTheryx has acquired the two leading producers of colostrum and related nutritional products, APS BioGroup, of Phoenix, and La Belle Associates, of Bellingham, WA. In March of 2016, PanTheryx announced that it entered into a $53 million financing with Pegasus Capital Advisors. The acquisitions were funded through a follow-on investment in PanTheryx by Pegasus Capital Advisors. The terms of the acquisitions were not released.

Colostrum is nature’s perfect first food. It is the pre-milk substance that is produced by all mammals and is the first passive immunity that any newborn receives. Bovine colostrum is a key ingredient in DiaResQ, a product manufactured and marketed by PanTheryx. DiaResQ provides important nutrients beneficial for people with diarrhea in order to rapidly restore normal digestive function. DiaResQ is helping to address the major global health concern of infectious diarrhea, which is a leading cause of death worldwide among children under the age of five. Colostrum is also an ingredient in a variety of animal and human health, wellness and nutritional products, and there is growing evidence to support its use as a component in microbiome-based therapeutics and medical foods which will lead to new applications and products.

“Colostrum has the ability to dramatically transform health and wellness globally, but its full potential has yet to be realized,” said Mark A. Braman, president and CEO of PanTheryx. “As a science driven company, PanTheryx has the resources and capabilities to aggressively advance research to support expanded commercial opportunities. We plan to invest heavily to unlock the full potential of colostrum.”

Independent of future discoveries, the intelligence firm Future Market Insights expects colostrum market revenue to rise to nearly $2 billion by 2026. To meet this increasing demand, PanTheryx is expanding manufacturing capacity at its Phoenix facility.

“As the only colostrum manufacturer with multiple production facilities, the infrastructure of the combined companies gives us the ability to ensure the supply of high quality, responsibly sourced colostrum to support the long-term requirements of current and future customers of APS and La Belle, as well as PanTheryx’s needs,” said Braman. “As a company, we are firmly committed to realizing the full potential of colostrum. By acquiring APS and La Belle, we have created the premier colostrum company capable of servicing the market and all of its needs.”

About PanTheryx:
Founded in 2007, PanTheryx™ is a global medical nutrition company based in Boulder, Colorado, and is dedicated to improving global health and quality of life through innovative life science. Utilizing its broad-based proprietary technology platform, PanTheryx is focused on the development and commercialization of medical nutrition products that target the gastrointestinal microbiome. For more information, please log on to

About DiaResQ:
The company’s flagship product, DiaResQ®, addresses acute infectious diarrhea, a leading cause of death worldwide among children under the age of five. It was recently named in the Reimagining Global Health report as one of the 30 leading healthcare innovations with great promise to transform global health by 2030 and to help accelerate progress toward new health targets proposed in the United Nations Sustainable Development Goals. DiaResQ is a food for special dietary use that provides beneficial nutrients for people with diarrhea. For more information, please visit

For PanTheryx
Tom Langford, 617-761-6775